Sight Sciences touts eye pressure reduction with glaucoma OMNI device

The US Food and Drug Administration (FDA) has cleared Sight Sciences’ OMNI surgical system to reduce intraocular pressure in patients with primary open-angle glaucoma.

Phalguni Deswal April 15 2024

US-based Sight Sciences has published the two-year post-surgical outcomes of its minimally invasive glaucoma surgery device, the OMNI surgical system.

The data from the real-world clinical outcomes study was published in the American Journal of Ophthalmology. The study collected data for 77,391 patients with open-angle glaucoma who either received cataract surgery or a combination of cataract surgery and intervention with either of the three US FDA minimally invasive glaucoma surgery devices.

The real-world data was collected from the US eye disease clinical registry, the American Academy of Ophthalmology IRIS registry. The three US FDA-approved devices included in the study were Sight Sciences’ OMNI surgical systems, Alcon’s Hydrus Microstent and Glaukos’ iStent inject.

At two years after receiving surgery with OMNI device, patients with high baseline intraocular pressure of over 18 millimetres of mercury (mmHg) observed a 30% mean reduction in pressure, compared with baseline. The patients who received cataract surgery alone demonstrated a 24% mean reduction in pressure, compared with baseline at two years. The patients with high baseline intraocular pressure also observed the greatest numerical reduction in medication use.

At two years after receiving surgery with the OMNI device, patients with low baseline intraocular pressure (less than 18 mmHg) observed a 3% mean reduction in pressure, compared with baseline. The patients who received cataract surgery alone demonstrated no mean reduction in pressure, compared with baseline at two years.

The OMNI device has been cleared by the US FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The device is designed to restore the natural outflow process of the eye by addressing the three areas of resistance associated with primary open-angle glaucoma.

Glaucoma is the leading cause of global irreversible blindness. A study estimates that the incidence of glaucoma is expected to reach 111.8 million in 2040. As per GlobalData analysis, the market for minimally invasive glaucoma surgery devices in the US is projected to be worth approximately $345m by 2030.

Another ophthalmic device in Sight Sciences’ catalogue includes TearCare technology for treating dry eye. The device has been cleared by the US FDA for the application of localised heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close